Hilton Head Capital Partners’s Novartis NVS Stock Holding History

Hilton Head Capital Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$416K	Buy	2,656 +5	+0.2%	+$750	0.21%	114
2026 Q1	$405K	Buy	2,651 +16	+0.6%	+$2.45K	0.23%	105
2025 Q4	$363K	Buy	+2,635	New	+$345K	0.21%	105

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hilton Head Capital Partners's NVS Position: Q2 2026 in Review

Hilton Head Capital Partners increased its Novartis (NVS) stake by 0.19% in Q2 2026, buying an estimated $750 and bringing the position to 2,656 shares worth $416K. The position accounts for 0.21% of the portfolio, ranked #114.

Hilton Head Capital Partners first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,615 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Hilton Head Capital Partners held 2,656 shares of Novartis worth $416K as of Q2 2026.
Hilton Head Capital Partners bought 5 Novartis shares in Q2 2026, an estimated $750.
Novartis made up 0.21% of Hilton Head Capital Partners's portfolio in Q2 2026, its #114 holding.
Hilton Head Capital Partners first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
1,615 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.